Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
出版年份 2021 全文链接
标题
Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
作者
关键词
Antipsychotic agents, Obesity, Metabolic Syndrome, Glucagon-like peptide receptors
出版物
PSYCHIATRY RESEARCH
Volume 299, Issue -, Pages 113830
出版商
Elsevier BV
发表日期
2021-02-24
DOI
10.1016/j.psychres.2021.113830
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- 20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings
- (2020) Taeho Greg Rhee et al. AMERICAN JOURNAL OF PSYCHIATRY
- The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials
- (2019) Davy Vancampfort et al. World Psychiatry
- Liraglutide and its Neuroprotective Properties—Focus on Possible Biochemical Mechanisms in Alzheimer’s Disease and Cerebral Ischemic Events
- (2019) Michał Wiciński et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Neuroprotective effects of the second generation antipsychotics
- (2019) Alexander T. Chen et al. SCHIZOPHRENIA RESEARCH
- Incretins in obesity and diabetes
- (2019) Chee W. Chia et al. Annals of the New York Academy of Sciences
- Cardiovascular risk and obesity
- (2019) C. Cercato et al. Diabetology & Metabolic Syndrome
- Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial
- (2019) Clare Alexandra Whicher et al. Trials
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
- (2018) Seong Hoon Jeong et al. Psychiatry Investigation
- Glucagon-like peptide-1 receptor-agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis
- (2018) Dan Siskind et al. DIABETES OBESITY & METABOLISM
- One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
- (2018) C. K. Svensson et al. ACTA PSYCHIATRICA SCANDINAVICA
- Treating loss-to-follow-up as a missing data problem: a case study using a longitudinal cohort of HIV-infected patients in Haiti
- (2018) Deanna P. Jannat-Khah et al. BMC PUBLIC HEALTH
- Practical Use of Pharmacotherapy for Obesity
- (2017) Leon I. Igel et al. GASTROENTEROLOGY
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
- (2016) Pelle L. Ishøy et al. DIABETES OBESITY & METABOLISM
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Activation of Nesfatin-1-Containing Neurones in the Hypothalamus and Brainstem by Peripheral Administration of Anorectic Hormones and Suppression of Feeding via Central Nesfatin-1 in Rats
- (2016) R. Saito et al. JOURNAL OF NEUROENDOCRINOLOGY
- BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
- (2016) Stephen J Cooper et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Timing the discussion of antiobesity medications during obesity treatment
- (2016) Candida J. Rebello et al. Obesity
- Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers
- (2016) Ken Fujioka et al. Obesity
- Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist
- (2016) Kenichi Katsurada et al. Journal of Diabetes Investigation
- Predicting therapeutic weight loss
- (2015) Nicholas Finer AMERICAN JOURNAL OF CLINICAL NUTRITION
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endogenous GLP-1 acts on paraventricular nucleus to suppress feeding: Projection from nucleus tractus solitarius and activation of corticotropin-releasing hormone, nesfatin-1 and oxytocin neurons
- (2014) Kenichi Katsurada et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
- (2014) Laurie L. Baggio et al. JOURNAL OF CLINICAL INVESTIGATION
- Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes
- (2014) Steven R. Smith et al. Obesity
- Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis
- (2013) Tejashree S. Dixit et al. PHYSIOLOGY & BEHAVIOR
- Review article: a comparison of glucagon-like peptides 1 and 2
- (2012) P. Janssen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
- (2012) Kerry Hunter et al. BMC NEUROSCIENCE
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
- (2011) Alex J. Mitchell et al. SCHIZOPHRENIA BULLETIN
- Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat
- (2011) G. C. Smith et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- Predictors of weight loss and maintenance in patients treated with antiobesity drugs
- (2011) Federica Guaraldi et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity
- (2010) Evgueni Tchoukhine et al. JOURNAL OF CLINICAL PSYCHIATRY
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity
- (2009) Grigori Joffe et al. JOURNAL OF CLINICAL PSYCHIATRY
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
- (2009) S. Leucht et al. PSYCHOLOGICAL MEDICINE
- Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: Implications for glucose metabolism and food choice behaviour
- (2009) Greg C. Smith et al. SCHIZOPHRENIA RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started